Manuel
Valladares Ayerbes
Instituto de Salud Carlos III
Madrid, EspañaPublications in collaboration with researchers from Instituto de Salud Carlos III (6)
2019
-
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446
2018
-
First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii183
-
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial
Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444
2017
-
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 498-507
2015
-
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324